BRTX
BioRestorative Therapies Inc

3,458
Mkt Cap
$12.69M
Volume
309,056.00
52W High
$2.55
52W Low
$1.10
PE Ratio
-0.95
BRTX Fundamentals
Price
$1.13
Prev Close
$1.43
Open
$1.41
50D MA
$1.49
Beta
1.15
Avg. Volume
291,783.04
EPS (Annual)
-$1.16
P/B
5.20
Rev/Employee
$36,454.54
Loading...
Loading...
News
all
press releases
BioRestorative Therapies (OTCMKTS:BRTXQ) Trading Up 6.4% - What's Next?
BioRestorative Therapies (OTCMKTS:BRTXQ) Shares Up 6.4% - Here's What Happened...
MarketBeat·2d ago
News Placeholder
More News
News Placeholder
Biorestorative Therapies, Inc. (BRTX) Reports Q3 Loss, Lags Revenue Estimates
Biorestorative Therapies (BRTX) delivered earnings and revenue surprises of 0.00% and -97.00%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·8d ago
News Placeholder
Earnings Outlook For BioRestorative Therapies
read more...
Benzinga·9d ago
News Placeholder
CRISPR Therapeutics AG (CRSP) Reports Q3 Loss, Lags Revenue Estimates
CRISPR Therapeutics (CRSP) delivered earnings and revenue surprises of +11.36% and -86.76%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·10d ago
News Placeholder
Is Bayer (BAYRY) Outperforming Other Medical Stocks This Year?
Here is how Bayer Aktiengesellschaft (BAYRY) and Biorestorative Therapies, Inc. (BRTX) have performed compared to their sector so far this year.
Zacks·1mo ago
News Placeholder
Are Medical Stocks Lagging Adaptive Biotechnologies (ADPT) This Year?
Here is how Adaptive Biotechnologies (ADPT) and Biorestorative Therapies, Inc. (BRTX) have performed compared to their sector so far this year.
Zacks·2mo ago
News Placeholder
Are Medical Stocks Lagging Black Diamond Therapeutics (BDTX) This Year?
Here is how Black Diamond (BDTX) and Biorestorative Therapies, Inc. (BRTX) have performed compared to their sector so far this year.
Zacks·3mo ago
News Placeholder
Biorestorative Therapies, Inc. (BRTX) Reports Q2 Loss, Beats Revenue Estimates
Biorestorative Therapies (BRTX) delivered earnings and revenue surprises of +26.83% and +51.50%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3mo ago
News Placeholder
Zymeworks Inc. (ZYME) Tops Q2 Earnings and Revenue Estimates
Zymeworks (ZYME) delivered earnings and revenue surprises of +105.77% and +256.65%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3mo ago
News Placeholder
Entrada Therapeutics, Inc. (TRDA) Reports Q2 Loss, Lags Revenue Estimates
Entrada Therapeutics (TRDA) delivered earnings and revenue surprises of -20.93% and -78.02%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·4mo ago

Latest BRTX News

View

Advertisement|Remove ads.

Advertisement|Remove ads.